12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Emtricitabine/tenofovir/rilpivirine regulatory update

Gilead submitted an MAA to EMA for a fixed-dose combination of Johnson & Johnson's rilpivirine and Gilead's Truvada emtricitabine/tenofovir to treat HIV-1...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >